Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826 Meeting Abstract
| Authors: | Rutherford, S. C.; Li, H.; Herrera, A. F.; Leblanc, M.; Ahmed, S.; Davison, K. L.; Casulo, C.; Bartlett, N. L.; Tuscano, J. M.; Hess, B.; Torka, P.; Kumar, P.; Jacobs, R. W.; Song, J. Y.; Castellino, S. M.; Kahl, B. S.; Leonard, J. P.; Smith, S. M.; Friedberg, J. W.; Evens, A. M. |
| Abstract Title: | Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826 |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 181 |
| Language: | English |
| ACCESSION: | WOS:001159306700182 |
| DOI: | 10.1182/blood-2023-180114 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
